Latest Content

Rina-S Yields 50% Response Rate in Advanced Endometrial Cancer

June 4th 2025, 3:00pm

By Spencer Feldman

Article

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.

Addressing Unmet Needs for Young Women Before, During and After a Cancer Diagnosis

June 4th 2025, 1:00pm

By Ryan Scott

Article

Natalie Schnaitmann discusses urgent supportive care gaps that affect long-term quality of life for younger women with cancer.

Imdelltra Shows Survival Benefit in Small Cell Lung Cancer

June 3rd 2025, 9:00pm

By Chris Ryan

Article

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC.

Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer

June 3rd 2025, 8:00pm

By Dr. Massimo Cristofanilli

Video

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

FDA Approves Nubeqa in Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025, 7:22pm

By Spencer Feldman

Article

The FDA approved Nubeqa for metastatic castration-sensitive prostate cancer based on significantly improved radiographic progression-free survival data.

You Are Not a Statistic: Facing Cancer With Hope, Not Numbers

June 3rd 2025, 5:00pm

By Linda Cohen

Article

I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story than the statistics.

Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC

June 3rd 2025, 4:00pm

By Jason M Broderick

Article

Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.

Kisqali Benefit Lasts Across Age in Breast Cancer Subset

June 3rd 2025, 3:00pm

By Gina Mauro

Article

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

COCOON Regimen Eases Dermatologic Side Effects After Treatment in EGFR+ NSCLC

June 3rd 2025, 2:00pm

By Russ Conroy

Article

The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC.

Akeega Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer

June 3rd 2025, 12:00pm

By Silas Inman

Article

Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.

Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer

June 2nd 2025, 9:00pm

By Dr. Sarah Sammons

Video

Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.

Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer

June 2nd 2025, 7:00pm

By Tim Cortese

Article

Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.

Fotivda Monotherapy Demonstrated Efficacy in Previously Treated Metastatic RCC

June 2nd 2025, 6:00pm

By Dr. Alexander Chehrazi-Raffle

Video

Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma.

Cancer Survivors Look Forward, Not Backward

June 2nd 2025, 5:00pm

By Jane Biehl Ph.D.

Article

As a cancer survivor I explain the importance of looking forward to life.

Initial Enhertu Combo Improves Survival in HER2+ Advanced Breast Cancer

June 2nd 2025, 4:00pm

By Russ Conroy

Article

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.